Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 19/20 | 0.56 |
| ▸ | RPS6KA2 | Q15349 | 4/20 | 0.48 |
| ▸ | RPS6KA1 | Q15418 | 2/20 | 0.48 |
| ▸ | RPS6KA6 | Q9UK32 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19252841 | 0.86 | RPS6KA3 (0.53) | RPS6KA3RPS6KA2RPS6KA1RPS6KA6 | |
| SCHEMBL5389081 | 0.84 | RPS6KA3 (0.53) | RPS6KA3RPS6KA2RPS6KA1RPS6KA6 | |
| SCHEMBL1982846 | 0.81 | RPS6KA3 (0.64) | RPS6KA3RPS6KA2RPS6KA1RPS6KA6 | |
| SCHEMBL1981787 | 0.81 | RPS6KA3 (0.64) | RPS6KA3RPS6KA2RPS6KA1RPS6KA6 | |
| SCHEMBL30137600 | 0.81 | RPS6KA3 (0.64) | RPS6KA3RPS6KA2RPS6KA1RPS6KA6 | |
| SCHEMBL1982725 | 0.81 | RPS6KA3 (0.64) | RPS6KA3RPS6KA2RPS6KA1RPS6KA6 | |
| SCHEMBL18573359 | 0.80 | RPS6KA3 (0.50) | RPS6KA3RPS6KA2RPS6KA1RPS6KA6 | |
| SCHEMBL5220213 | 0.80 | RPS6KA3 (0.50) | RPS6KA3RPS6KA2RPS6KA1RPS6KA6 | |
| SCHEMBL5388590 | 0.80 | RPS6KA3 (0.50) | RPS6KA3RPS6KA2RPS6KA1RPS6KA6 | |
| SCHEMBL5760326 | 0.80 | RPS6KA3 (0.54) | RPS6KA3RPS6KA2RPS6KA1RPS6KA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7098337-B2 | 1,2,3,4,9,9a-hexahydro-2,4a,5-triaza-fluorene and 1,2,3,4-tetrahydro-2,4a,5-triaza-fluorene derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-08-29 | — | — | US | disclosed |
| EP-1472255-B1 | AZA-ARYLPIPERAZINES | HOFFMANN LA ROCHE (CH) | 2006-03-01 | — | — | EP | disclosed |
| EP-1472255-A1 | AZA-ARYLPIPERAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-03 | — | — | EP | disclosed |
| US-20030207888-A1 | Piperazine derivatives | F.HOFFMANN-LA ROCHE AG (CH) | 2003-11-06 | — | — | US | disclosed |
| WO-2003064423-A1 | AZA-ARYLPIPERAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207888-A1 | Piperazine derivatives | GPR119, CPT1B, CYP2E1 | RPS6KA3 3909/4885RPS6KA2 3947/4885RPS6KA1 2882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.